Core Demand of the Question
- Examine the affordability in India’s generic pharmaceutical landscape.
- Examine the limitation in balancing affordability with quality in India’s generic pharmaceutical landscape.
- Highlight the challenges posed by decentralized drug regulations, variations in manufacturing standards, and non-uniform enforcement mechanisms.
- Suggest a way ahead
|
Answer
India’s generic pharmaceutical sector, which supplies over 60% of the world’s vaccines and 20% of all generic medicines, is central to global healthcare affordability. However, the interplay between affordability and quality faces significant challenges. Decentralized drug regulations, variations in manufacturing standards, and inconsistent enforcement mechanisms lead to discrepancies in drug quality, with about 1.5% of medicines failing quality tests in the country. This impacts patient safety and undermines healthcare outcomes.
Enroll now for UPSC Online Course
Affordability in India’s Generic Pharmaceutical Landscape
- Cost-effectiveness through economies of scale: India leverages its vast manufacturing base and low production costs to produce affordable generic medicines, reducing healthcare expenditure.
For example: Generic medicines sold under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana have saved consumers ₹30,000 crore over the last decade.
- Reduction in out-of-pocket expenditure: Affordable generics contribute to minimizing out-of-pocket healthcare costs, which constitute a significant share of health expenditure in India.
For example: In 2021-22, out-of-pocket healthcare expenditure stood at 39.4% of total health expenditure, where generics played a key role in providing cost-effective solutions.
- Increased treatment adherence: Low-cost generics improve patient adherence to prescribed treatments, ensuring consistent care and better health outcomes.
For example: Affordable antidiabetic generics enable broader access to essential treatment for chronic conditions in low-income populations.
- Export of affordable medicines globally: India’s generic pharmaceutical industry supplies cost-effective medicines to developing countries, enhancing global healthcare accessibility.
For example: India is often referred to as the “pharmacy of the world” for its role in supplying affordable generics internationally, especially during the COVID-19 pandemic.
- Support from government programs: Schemes like the Pradhan Mantri Bhartiya Janaushadhi Pariyojana promote affordability through government-subsidized generic drug stores.
For example: Generic medicines worth ₹5,600 crore were sold under this scheme by August 2024.
- Bioequivalence to branded drugs: Generics are designed to be bioequivalent to their branded counterparts, offering the same therapeutic effects at a fraction of the price.
For example: Generic antibiotics and antihypertensive drugs provide similar efficacy to branded ones, making treatment accessible to economically weaker sections.
Limitations in Balancing Affordability with Quality
- Quality control lapses: Inconsistent quality standards and regulatory oversight undermine the effectiveness and safety of generic drugs.
For example: A study by PGIMER found that generic itraconazole achieved therapeutic drug levels in only 29% of patients within two weeks, compared to 73% for the innovator drug.
- Variability in excipients and manufacturing processes: Differences in excipients and production methods can impact drug stability, absorption, and bioavailability, compromising therapeutic outcomes.
For instance: Generic capsules with uneven pellet sizes showed delayed drug release, requiring dose escalation or switching to the innovator drug.
- Regulatory arbitrage due to decentralization: Fragmented drug regulation by State Drug Regulatory Authorities (SDRAs) allows manufacturers to exploit weaker oversight, leading to inconsistent quality.
For example: The Central Drugs Standard Control Organisation (CDSCO) has limited power, relying on States to enforce quality standards effectively.
- Inadequate enforcement of stability testing: Stability testing mandated by the CDSCO in 2018 is inconsistently implemented, resulting in generics with poor shelf life and efficacy.
For instance: Drugs approved before 2018 often bypass these requirements, perpetuating the availability of substandard medications.
- Lax impurity standards in Indian Pharmacopoeia: Higher permissible impurity levels compared to U.S. and EU standards compromise the safety of generics in India.
For example: The rejection of stricter ICH guidelines by the CDSCO and Pharmacopoeia Commission on cost grounds highlights this gap.
- Bioequivalence thresholds for narrow therapeutic index drugs: The allowable bioequivalence range of 80%-125% is insufficient for drugs with narrow therapeutic indices, leading to subtherapeutic effects or adverse reactions.
For instance: Fluctuations in drug levels for life-saving medications like anticoagulants have been observed in generic versions due to inadequate thresholds.
- Lack of centralization in drug regulation: India’s decentralized drug regulation system hinders the establishment of uniform quality standards.
For example: Recommendations by the Bhatia (1954), Hathi (1975), and Mashelkar (2003) committees for centralized oversight have yet to be fully implemented, perpetuating regulatory disparities.
Challenges Posed by Decentralized Drug Regulations
- Inconsistent Quality Standards Across States: India’s decentralized drug regulation system allows State Drug Regulatory Authorities (SDRAs) to set their own standards, leading to discrepancies in drug quality.
For instance: Weak oversight in some states allows manufacturers to exploit regulatory gaps, leading to the circulation of substandard generics.
- Limited Authority of the Central Regulatory Body: The Central Drugs Standard Control Organisation (CDSCO) lacks enforcement power, reducing its ability to ensure uniform quality nationwide.
For instance: The CDSCO can only recommend actions against manufacturers, leaving critical enforcement to State authorities, which may lack resources or willpower.
- Regulatory Arbitrage: Manufacturers may relocate to states with less stringent regulations to avoid stricter compliance.
For instance: Pharmaceutical companies have been known to shift operations to states with lax inspection systems, undermining the quality assurance process.
- Lack of Coordination Between States and Centre: Fragmented authority leads to duplication of efforts and delays in addressing quality concerns.
For instance: A delayed response to substandard itraconazole generics due to poor coordination highlighted the inefficiencies of decentralized regulation.
Check Out UPSC CSE Books From PW Store
Challenges Posed by Variations in Manufacturing Standards
- Differences in Excipients: Variability in binders, fillers, and coatings impacts drug absorption and therapeutic outcomes.
For example: The PGIMER study showed that generics of itraconazole had fewer and unevenly sized pellets, compromising bioavailability.
- Inconsistent Manufacturing Processes: Variations in equipment and methods like granulation and compression lead to fluctuations in drug properties.
For example: Generic drugs releasing active pharmaceutical ingredients (API) more rapidly caused drug level fluctuations, affecting efficacy.
- Subpar Tablet Design: Physical defects, such as irregular tablet hardness and porosity, disrupt drug disintegration and absorption.
For example: Defects in generic itraconazole capsules delayed therapeutic drug levels compared to innovator drugs.
- Lack of Advanced Technology in Production: Many manufacturers lack access to state-of-the-art technologies for consistent manufacturing.
For example: Small-scale units in India often use outdated equipment, making it difficult to replicate the innovator’s sustained-release mechanisms.
- Inadequate Stability Testing: Limited enforcement of stability protocols leads to substandard drugs, especially in diverse climatic conditions.
For example: Stability testing mandates by the CDSCO in 2018 remain poorly implemented, with pre-2018 generics escaping scrutiny.
- Higher Permissible Impurity Levels: The Indian Pharmacopoeia allows higher impurity thresholds than international standards, risking drug safety.
For example: Rejection of stricter ICH guidelines due to cost concerns perpetuates the presence of impure drugs in the market.
- Lack of Periodic Reassessment: Generics approved in the past are rarely reassessed for quality compliance under current standards.
For example: Many long-standing generic drugs in India do not meet the updated regulatory benchmarks for bioequivalence and stability.
- Shortage of Testing Facilities: Insufficient central drug-testing laboratories hampers the effective monitoring of drug quality.
For instance: Overburdened state labs fail to conduct timely inspections, allowing substandard drugs to persist in the supply chain.
Way Ahead to Address Challenges in India’s Generic Pharmaceutical Landscape
- Centralize Drug Regulation: Establish a centralized regulatory body, like the USFDA, to ensure uniform enforcement of quality standards across India.
For example: The EMA’s centralized framework has maintained consistent drug standards across Europe, ensuring uniformity.
- Stability Testing: Mandate uniform stability testing protocols for all generic drugs to ensure efficacy under diverse climatic conditions.
For example: The WHO guidelines for tropical regions can serve as a model for India’s varied climatic zones.
- Manufacturing Standards: Implement stricter manufacturing standards for excipients and formulations to ensure consistency.
- Enforcement Mechanisms: Equip State Drug Regulatory Authorities (SDRAs) with standardized training and clear enforcement guidelines.
For example: Disparities in regulatory oversight, like those in Uttar Pradesh, affect drug quality consistency across states.
- Public Confidence: Launch nationwide awareness campaigns to build public confidence in the safety and efficacy of generics.
For example: The PMBJP has improved trust in generics by making affordable medicines available to a wide population.
- Technology Integration: Leverage digital tools like blockchain to ensure transparency and traceability in drug manufacturing and distribution.
For example: DAVA (Drug Authentication and Verification Application) has been effective in reducing counterfeit medicines in India.
Enroll now for UPSC Online Classes
Achieving a balance between affordability and quality in India’s generic pharmaceutical sector requires addressing regulatory fragmentation and enhancing manufacturing standards. A unified regulatory framework, consistent enforcement, and investment in quality assurance can help bridge the gap. A collaborative approach can ensure that both affordability and quality are prioritized for the betterment of public health.
Latest Comments